5-(1'-naphthylidene)-2,4-dioxotetrahydro-1,3-thiazole | 139336-30-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 5-(1'-naphthylidene)-2,4-dioxotetrahydro-1,3-thiazole
• 英文别名: 5-[1]naphthylmethylene-thiazolidine-2,4-dione；5-[1]Naphthylmethylen-thiazolidin-2,4-dion；5-(4-dimethylaminobenzylidene)thiazolidine-2,4-dione；5-naphthalen-1-ylmethylenethiazolidine-2,4-dione；(5Z)-5-(naphthalen-1-ylmethylidene)-1,3-thiazolidine-2,4-dione
• CAS: 139336-30-4
• 化学式: C₁₄H₉NO₂S
• 分子量: 255.297
• InChiKey: WMHVUSFNJBJQQB-WQLSENKSSA-N

物化性质

• 密度：
  1.425±0.06 g/cm3(Predicted)
• 溶解度：
  >38.3 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  71.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-(1'-naphthylidene)-2,4-dioxotetrahydro-1,3-thiazole 在 盐酸 、 potassium carbonate 、 溶剂黄146 作用下， 以 丙酮 为溶剂， 反应 26.0h， 生成 (Z)-2-(5-(naphthalen-1-ylmethylene)-2,4-dioxothiazolidin-3-yl)acetic acid
  参考文献：
  名称：

  Structure–activity relationships and molecular modelling of 5-arylidene-2,4-thiazolidinediones active as aldose reductase inhibitors

  摘要：

  The structure-activity relationships (SARs) of 5-arylidene-2,4-thiazolidinediones active as aldose reductase inhibitors (ARIs) were extended by varying the substitution pattern on the 5-arylidene moiety and on N-3. In particular, the introduction of an additional aromatic ring or an H-bond donor group on the 5-benzylidene ring enhanced ALR2 inhibitory potency. Moreover, the presence of a carboxylic anionic chain on N-3 was shown to be an important, although not essential, structural requisite to produce high levels of ALR2 inhibition. The length of this carboxylic chain was critical and acetic acids 4 were the most effective inhibitors among the tested derivatives. Molecular docking simulations into the ALR2 active site accorded with the in vitro inhibition data. They allowed the rationalization of the observed SARs and provided a pharmacophoric model for this class of ARIs. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.02.026
• 作为产物：
  描述：

  2,4-噻唑烷二酮 、 1-萘甲醛 在 哌啶 作用下， 以 乙醇 为溶剂， 反应 24.0h， 以88%的产率得到5-(1'-naphthylidene)-2,4-dioxotetrahydro-1,3-thiazole
  参考文献：
  名称：

  寻找多靶点配体作为糖尿病及其并发症的潜在药物——醛糖还原酶和蛋白酪氨酸磷酸酶1B抑制剂的构效关系研究

  摘要：

  糖尿病 (DM) 是一种复杂的疾病，目前影响超过 4.6 亿人，是全球主要的死亡原因之一。它的发展意味着许多代谢功能障碍和高血糖引起的慢性并发症的发生。可以合理设计多种配体用于治疗多因素疾病，例如 DM，其精确目标是同时控制与疾病相关的多种致病机制，并提供比选择性药物组合更有效、更安全的治疗方法。我们之前的研究结果强调了靶向醛糖还原酶 (AR) 和蛋白酪氨酸磷酸酶 1B (PTP1B) 的可能性，这两种酶与 DM 及其并发症的发展密切相关，我们合成了 3-(5-arylidene-4-oxothiazolidin-3-yl) 丙酸和类似的 2-丁烯酸衍生物，目的是平衡双 AR/PTP1B 抑制剂的有效性，我们已将其鉴定为设计的多配体 (DMLs) ）。在测试的化合物中，4f 在低微摩尔浓度下表现出均衡的 AR/PTP1B 抑制作用，以及在鼠 C2C12 细胞培养物中有趣的胰岛素敏化活性。此处强调的

  DOI：

  10.3390/molecules26020330

文献信息

• Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer
  申请人：——

  公开号：US20030229120A1

  公开（公告）日：2003-12-11

  Novel ligands for the HisB10 Zn 2+ sites of the R-state insulin hexamer that are capable of prolonging the action of insulin preparations are disclosed.

  揭示了能够延长胰岛素制剂作用的R-态胰岛素六聚体的HisB10 Zn2+位点的新配体。
• [EN] PHAMACEUTICAL PREPARATIONS COMPRISING INSULIN<br/>[FR] PREPARATIONS PHARMACEUTIQUES CONTENANT DE L'INSULINE
  申请人：NOVO NORDISK AS

  公开号：WO2006005683A1

  公开（公告）日：2006-01-19

  Novel preparations comprising ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer wherein the ligand is extended by protamine that are capable of prolonging the ac­tion of insulin preparations.

  新型制剂包括配体，用于R-态胰岛素六聚体的HisB10 Zn2+位点，其中配体通过精氨酸延长，能够延长胰岛素制剂的作用。
• Stabilised insulin compositions
  申请人：Kaarsholm Christian Niels

  公开号：US20050065066A1

  公开（公告）日：2005-03-24

  The present invention provides pharmaceutical compositions comprising insulin and novel ligands for the His B10 Zn 2+ sites of the R-state insulin hexamer. The resulting preparations have improved physical and chemical stability.

  本发明提供了包含胰岛素和新型配体的药物组合物，用于R-态胰岛素六聚体的His B10 Zn2+位点。由此制备的药物具有改善的物理和化学稳定性。
• [EN] PHARMACEUTICAL PREPARATIONS COMPRISING ACID-STABILISED INSULIN<br/>[FR] PREPARATIONS PHARMACEUTIQUES CONTENANT DE L'INSULINE STABILISEE D'UN POINT DE VUE ACIDE
  申请人：NOVO NORDISK AS

  公开号：WO2004080480A1

  公开（公告）日：2004-09-23

  Novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer that are capable of prolonging the action of insulin preparations are disclosed.

  揭示了能够延长胰岛素制剂作用的R态胰岛素六聚体的HisB10 Zn2+位点的新配体。
• 5-Arylidene-4-Thiazolidinone Derivatives Active as Antidegenerative Agents on Human Chondrocyte Cultures
  作者：Annamaria Panico、Rosanna Maccari、Venera Cardile、Lucia Crasci、Simone Ronsisvalle、Rosaria Ottana

  DOI：10.2174/157340613804488378

  日期：2013.2.1

  5-Arylidene-2-oxo-4-thiazolidinones and 2-phenylimino analogues were evaluated for their antidegenerative activity on human chondrocyte cultures stimulated by IL-1β and for their inhibitory capability against matrix metalloproteinase- 13. Our results indicated that 5-arylidene-4-thiazolidinone derivatives 1-9 exhibit antidegenerative activity and could block multiple cartilage destruction during the osteoarthritic process. Out of the selected compounds, (5-arylidene- 2,4-dioxothiazolidin-3-yl)acetic acids 7-9 showed significant effectiveness in reducing NO release and restoring normal levels of GAGs in chondrocytes treated with IL-1β. Moreover, benzoic acids 1, 5 and 6 proved to be effective MMP-13 inhibitors and were able to restore normal levels of GAGs.

  5-芳基亚乙烯基-2-氧基-4-噻唑烷酮和2-苯基亚胺类似物被评估其在IL-1β刺激下的人类软骨细胞培养中的抗退化活性及其对基质金属蛋白酶-13的抑制能力。我们的结果表明，5-芳基亚乙烯基-4-噻唑烷酮衍生物1-9表现出抗退化活性，能够在骨关节炎过程中阻止多重软骨破坏。在选择的化合物中，(5-芳基-2,4-二氧噻唑烷-3-基)乙酸7-9在减少NO释放和恢复接受IL-1β处理的软骨细胞正常GAGs水平方面显示出显著效果。此外，苯甲酸1、5和6被证实为有效的MMP-13抑制剂，并能够恢复正常的GAGs水平。